Advancing Clinical Biomarkers for Immune Reset to Definitively Characterize the B-Cell Repertoire & Success of Cell Therapies & T-Cell Engagers

Join this workshop to explore how immune resetting is being measured in the clinic:

• Assessment of B-cell reset in peripheral blood and tissue biopsies across autoimmune diseases
• Comparison of B-cell dynamics in lupus, rheumatoid arthritis, and Sjögren’s disease, including B-cell phenotyping and the impact of prior therapies
• CD19 T-cell engager development: expectations for detecting immune reset during dose escalation and the potential implications for Phase 2 dose and schedule selection
• B cell depletion and reconstitution following dual CD19/BCMA CART targeting in SLE/LN
• Phenotypes of B cells pre-treatment and post-reconstitution
• Potential comparison to other B cell targeting therapies